ChemicalBook > Product Catalog >API >Inhibitors >Crizotinib

Crizotinib

Crizotinib Suppliers list
Company Name:ShangHai Biochempartner Co.,Ltd  Gold
Tel:+86 13818785766,400-021-9906
Email:gaoqing@biochempartner.com
Products Intro: Product Name:PF-2341066(Crizotinib)
CAS:877399-52-5
Purity:>98% .NMR+LCMS Package:50Mg/100Mg/500Mg/1g/5g/10g/
Company Name:Zaozhuang Benefit Chemical Co., Ltd.  Gold
Tel:+86 (632)4400267;13210772002;QQ:1948129184
Email:yzhchem@hotmail.com
Products Intro: Product Name:Crizotinib
CAS:877399-52-5
Purity:99% HPLC Package:1G;10G;100G;500G
Company Name:Shanghai Better-In Pharmaceutical Technology Co.,Ltd.  Gold
Tel:+86-21-38921049
Email:sales@better-in.com
Products Intro: Product Name:3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-Pyridinamine
CAS:877399-52-5
Purity:98% Package:1kg,5kg,25kg
Company Name:Wuhan Bo-Sen Biological Technology Co., Ltd  Gold
Tel:027-51335350 15107175693
Email:bosenyuan@foxmail.com
Products Intro: Product Name:Crizotinib; 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-Pyridinamine;
CAS:877399-52-5
Purity:99.0% Package:100G 500G 1KG
Company Name:SPIRO PHARMA  Gold
Tel:-
Email:eric_feng1954@126.com
Products Intro: Product Name:Crizotinib
CAS:877399-52-5
Purity:95% -98%HPLC Package:1GR;10GR;50GR;100GR;250GR;500GR;1KG;5KG;10KG;100KG
Crizotinib Basic information
Non-small cell lung cancer treatment Biological Activity Mechanism of action side effects FDA Approves Crizotinib Capsules
Product Name:Crizotinib
Synonyms:3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-Pyridinamine;(R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine;3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]pyridin-2-amine;Crizotinib;PF 2341066;PF-02341066;PF-2341066/Crizotinib;3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine
CAS:877399-52-5
MF:C21H22Cl2FN5O
MW:450.343
EINECS:
Product Categories:Aromatic;Chiral Reagents;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pfizer Compounds;Pharmaceuticals;Inhibitor;Anti-cancer & immunity
Mol File:877399-52-5.mol
Crizotinib Structure
Crizotinib Chemical Properties
Safety Information
HazardClass IRRITANT
MSDS Information
Crizotinib Usage And Synthesis
Non-small cell lung cancer treatmentCrizotinib is targeted drug for treatment of non-small cell lung cancer cell developed by the American Pfizer Company, with the trade name being Xalkori. Xalkori is the frontier and groundbreaking drug in the filed of targeted therapy of the lung cancer. It was approved for entering into the United State Market at August 2011 and had been also written into the international guideline for lung cancer treatment by the end of that year. As a first-line treatment drug in patients with ALK-positive, another stuff which was approved together with Crizotinib was the first genetic diagnosis approach-Vysis ALK Break Apart FISH Probe Kit which had used fluorescence in situ hybridization (FISH) for the first time. This is this approach currently used in global clinical trials for detecting the EML4-ALK fusion gene in the NSCLC. This detection will help identify patients that could benefit from the therapy of Crizotinib.
On February 25, 2013, Pfizer announced that the Xalkori XALKORI (Crizotinib) capsules had been approved by China State Food and Drug Administration (SFDA) in recent time. This is the first drug determined by the detection method approved by SFDA for being applied to the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with positive symptoms of anaplastic lymphoma kinase (ALK).
Xalkori has opened a new chapter of individualized treatment of lung cancer so that the doctors can provide the right treatment for the right patient. In the clinical trials of Xalkori, the test program requires the analysis results of the tumor biomarker ALK fusion gene to be positive, in order to increase the likelihood of responding to treatment. This detection method for the treatment of lung cancer for the first time allows researchers to observe good therapeutic effect in the patient population from pre-screen. In two multi-center single arm clinical trials (Test A and Test B), a study of 255 patients with locally advanced or metastatic non-small cell lung cancer ALK- positive (NSCLC) patients had showed the objective alleviating rates were 51% and 61%, respectively. The preliminary epidemiological studies have shown that in non-small cell lung cancer (NSCLC), the ALK-positive rate is about 3-5%, which means that each year there are about 46,000 to 28,000 ALK-positive non-small cell lung cancer (NSCLC) patients in the world.
From the publication of the result of the ALK fusion gene in the non-small cell lung cancer (NSCLC) to FDA approval, the study and development of Xalkori only takes four years. This is a major initiative in the field of oncology. This has once again showed the importance of close cooperation in various parties including academic research, pharmaceutical, diagnostics and drug administration and other regulatory authorities. From the novel drug application in China to the SFDA approval today, due to the inclusion of the fast-track passage of the national Center for Drug Evaluation, the entire process takes only about 11 months.
The resistance to the crizotinib is the major problem in the treatment of the patients of non-small cell lung cancer with positive ALK gene rearrangement. This resistance usually occurs within the first year of treatment with crizotinib. Among them, the drug resistance of 1/3 of the patients is caused by the ALK tyrosine kinase gene mutation or ALK gene amplification caused. Ceritinib is a kind of the second-generation oral ALK tyrosine kinase inhibitors. It is not acting on the MET proto-oncogene, but instead inhibiting the insulin-like growth factor 1 receptor. In the pre-clinical models, the anti-tumor effect via inhibitory of ALK of Ceritinib is 20 times as high as crizotinib. Studies have found that Ceritinib is still effective in the treatment of the crizotinib tolerated central nervous system lesions (NSCLC). The median progression-free survival period was 6.9 months for applying Ceritinib to NSCLC patients who have been subject to crizotinib treatment while this value is 10.4 months for patients free of treatment of crizotinib. The preliminary molecular analysis of some patients has found that no matter whether the ceritinib resistance mechanism is ALK-dependent or non-dependent, it has clinical benefit for the majority of patients. The findings suggest that: ceritinib can effectively inhibit ALK target and may act on an unknown but drug resistance-associated kinase. From this perspective, it is apparent that the crizotinib resistance issue should be able to be overcome.
The above information is edited by the chemicalbook of Dai Xiongfeng.
Biological ActivityPotent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50 values are 8.0 and 20 nM respectively). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable.
Mechanism of actionCrizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d’Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in the activation and dysregulation of the gene's expression and signaling, which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrates concentration-dependent inhibition of ALK and c-Met phosphorylation in cell-based assays using tumor cell lines, and also demonstrates antitumor activity in mice bearing tumor xenografts that express EML4- or NPM-ALK fusion proteins or c-Met.Crizotinib is a multitargeted small molecule tyrosine kinase inhibitor, which had been originally developed as an inhibitor of the mesenchymal epithelial transition growth factor (c-MET); it is also a potent inhibitor of ALK phosphorylation and signal transduction. This inhibition is associated with G1-S phase cell cycle arrest and induction of apoptosis in positive cells in vitro and in vivo. Crizotinib also inhibits the related ROS1 receptor tyrosine kinase.
References
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3876666/
side effectscrizotinib (Xalkori) is an oral receptor tyrosine kinase inhibitor indicated for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). Common side effects with Xalkori use include upper respiratory infection, nausea, vomiting, stomach pain, decreased appetite, insomnia, dizziness, tired feeling, diarrhea, constipation, rash or itching, cold symptoms (stuffy nose, sneezing, sore throat), numbness or tingling, or swelling in your hands or feet.
http://www.rxlist.com/xalkori-side-effects-drug-center.htm
FDA Approves Crizotinib CapsulesOn March 11, 2016, the U. S. Food and Drug Administration approved crizotinib capsules (Xalkori, Pfizer, Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. Crizotinib was first approved in 2011 for the treatment of patients whose tumors are anaplastic lymphoma kinase (ALK)-positive.

The current approval was based on a multicenter, single-arm trial in patients with metastatic ROS1 rearrangement-positive NSCLC.  All patients received crizotinib 250 mg orally twice daily. The efficacy outcome measures were objective response rate (ORR) according to RECIST v1.0 as evaluated by an independent radiology review (IRR) and as evaluated by the investigators. Duration of response (DoR) was an additional outcome measure.

The trial enrolled 50 patients with an age range of 25-77 years whose tumors were prospectively determined to be ROS1-positive by fluorescence in situ hybridization (FISH; 96%) or reverse transcription polymerase chain reaction (RT-PCR; 4%) clinical trial assays. The ORR by IRR was 66% (95% CI: 51%, 79%) with a median DoR of 18 months. The ORR according to investigators was 72% (95% CI: 58%, 84%).

The safety results of this trial were generally consistent with the safety profile of crizotinib evaluated in 1,669 patients with ALK-positive metastatic NSCLC. The most common adverse reactions of Xalkori are vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, and neuropathy.

The recommended dose and schedule for crizotinib is 250 mg capsules taken by mouth twice daily.

http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm490391.htm
Chemical PropertiesWhite Solid
UsageA potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). A potential antitumor agent.
UsageCrizotinib is a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Crizotinib is a potential antitumor agent.
UsagePF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley
Crizotinib Preparation Products And Raw materials
Tag:Crizotinib(877399-52-5) Related Product Information
Bortezomib Ceritinib Trametinib (GSK1120212) Erlotinib hydrochloride N-(3-(5-(4-Chlorophenyl)-1H-pyrrolo[2,3-B]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonaMide Olaparib